Changmao Biochemical Engineering Company Limited provided consolidated earnings guidance for the six months ended June 30, 2022. For the period, the company is likely to record a consolidated net profit attributable to the equity holders of the Company for 1H2022 of an amount ranging between RMB 35 million to RMB 45 million, represent a significant increase compared to the consolidated net profit attributable to the equity holders of the Company of approximately RMB 0.24 million for the six months ended 30 June 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.45 HKD | -1.10% | +2.27% | -23.73% |
03-26 | Changmao Biochemical Engineering Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
02-29 | Changmao Biochemical Engineering to Swing to Loss in 2023 | MT |
1st Jan change | Capi. | |
---|---|---|
-23.73% | 30.48M | |
+2.46% | 102B | |
-8.98% | 60.79B | |
+74.76% | 48.86B | |
+13.97% | 37.96B | |
+4.56% | 32.37B | |
+14.72% | 20.64B | |
+11.17% | 16.58B | |
+8.81% | 13.93B | |
-3.19% | 13.25B |
- Stock Market
- Equities
- 954 Stock
- News Changmao Biochemical Engineering Company Limited
- Changmao Biochemical Engineering Company Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2022